Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis

Souza, Renan P.; Luca, Vincenzo De; Muscettola, Giovanni; Rosa, Daniela V.; Bartolomeis, Andrea de; Romano-Silva, Marco Aurélio; Kennedy, James L.

doi:10.1016/j.pnpbp.2008.08.014

Cited by 32 publications

(26 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the variant has also been found to be associated with medication-induced metabolic disturbances (Hauner et al, 2003;Peters et al, 2008;Souza et al, 2008;Wang et al, 2005). The preliminary results from our laboratory also showed the variant to be associated with valproate-induced metabolic disturbance in patients with bipolar disorder (Chang et al, , 2010a.…”

Section: Discussionsupporting

confidence: 55%

Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers — A SPECT study

et al. 2011

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 55%

Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers — A SPECT study

et al. 2011

View full text Add to dashboard Cite

“…Some factors may potentially interact with bariatric surgery and result in highly variable outcomes in terms of weight loss and glycemic control afterwards. Much obesity research suggests that genes are strongly implicated in obesity and weight gain [17,37,38]. Evidence also shows that genes not only affect weight gain but also interact with other medical factors to influence weight loss and glycemic control [39][40][41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

ESR1, FTO, and UCP2 Genes Interact with Bariatric Surgery Affecting Weight Loss and Glycemic Control in Severely Obese Patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…-825C/T T allele was associated with higher AIWG in several studies, and with a nonsignificant trend in a meta-analysis Ujike et al, 129 Wang et al, 138 Souza et al 184 …”

Section: Gnb3mentioning

confidence: 96%

Pharmacogenetics of Antipsychotics

2014

View full text Add to dashboard Cite

Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects. These studies aimed to improve clinical care by predicting outcome of treatment with APs and thus allowing for individualized treatment strategies. We highlight most important findings obtained through both candidate gene and genome-wide association studies, including pharmacokinetic and pharmacodynamic factors. Methods:We reviewed studies on pharmacogenetics of AP response and adverse effects published on PubMed until early 2012. Owing to the high number of published studies, we focused our review on findings that have been replicated in independent studies or are supported by meta-analyses.Results: Most robust findings were reported for associations between polymorphisms of the cytochrome P450 system, the dopamine and the serotonin transmitter systems, and dosage, treatment response, and adverse effects, such as AP-induced weight gain or tardive dyskinesia. These associations were either detected for specific medications or for classes of APs. Conclusion:First promising and robust results show that pharmacogenetics bear promise for a widespread use in future clinical practice. This will likely be achieved by developing algorithms that will include many genetic variants. However, further investigation is warranted to replicate and validate previous findings, as well as to identify new genetic variants involved in AP response and for replication of existing findings. W W W La pharmacogénétique des antipsychotiquesObjectif : Au cours des dernières décennies, des efforts croissants ont été déployés dans des études visant à percer l'influence des facteurs génétiques sur le dosage des antipsychotiques (AP), la réponse au traitement, et la survenue d'effets indésirables. Ces études voulaient améliorer les soins cliniques en prédisant le résultat du traitement par AP, et en donnant lieu ainsi à des stratégies de traitement individualisées. Nous présentons les résultats les plus importants obtenus par des études tant de gènes candidats que d'association pangénomique, notamment les facteurs pharmacocinétiques et pharmacodynamiques. Méthodes :Nous avons passé en revue les études sur la pharmacogénétique de la réponse aux AP et des effets indésirables publiées dans PubMed jusqu'au début de 2012. Vu le nombre élevé d'études publiées, notre revue a mis l'accent sur les résultats qui ont été reproduits dans des études indépendantes ou qui sont soutenus par des méta-analyses.

show abstract

Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis

Cited by 32 publications

References 44 publications

Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers — A SPECT study

Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers — A SPECT study

ESR1, FTO, and UCP2 Genes Interact with Bariatric Surgery Affecting Weight Loss and Glycemic Control in Severely Obese Patients

Pharmacogenetics of Antipsychotics

Contact Info

Product

Resources

About